iSpecimen Inc. Write off of Deferred Debt Issuance Cost
iSpecimen Inc. (ISPC) reported Write off of Deferred Debt Issuance Cost of $27.57 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2022-03-22
- iSpecimen Inc. write off of deferred debt issuance cost for the quarter ending 2021-12-31 was $0.00.
- iSpecimen Inc. write off of deferred debt issuance cost for the quarter ending 2021-09-30 was $2.00.
- iSpecimen Inc. write off of deferred debt issuance cost for fiscal 2021 was $27.57K.
| Period end | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 6 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $2.00 derived: sum of 2 quarters · filed 2022-03-22 | $27.57K 10-K · filed 2022-03-22 | |
| 2021-09-30 | $2.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $27.57K 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | $27.57K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |